Navigation Links
AutoImmune Inc. Reports 2009 First Quarter Financial Results
Date:5/7/2009

PASADENA, Calif., May 7 /PRNewswire-FirstCall/ -- AutoImmune Inc. (OTC Bulletin Board: AIMM) today reported a net loss of $170,000, or $0.01 per share basic and diluted, for the three months ended March 31, 2009, compared with a net loss of $107,000, or $0.01 per share basic and diluted, for the three months ended March 31, 2008. As of March 31, 2009, the Company reported $8.5 million in cash and marketable securities, the same amount reported as of December 31, 2008.

Chairman of the Board and Chief Executive Officer Robert C. Bishop, Ph.D. stated, "Product sales in the first quarter of 2009 at Colloral LLC, our joint venture with Deseret Laboratories, Inc., were up from the fourth quarter of 2008 and from the first quarter of 2008. The response to marketing through our licensee, Bronson Laboratories, LLC remains encouraging." AutoImmune consolidates Colloral LLC for financial reporting purposes in accordance with FIN 46R "Consolidation of Variable Interest Entities."

AutoImmune has exclusively licensed certain of its intellectual property rights to BioMS Medical Corp., a Canadian company. Under the license agreement, BioMS makes monthly diligence payments to AutoImmune and will pay royalties to AutoImmune on sales of its lead drug, dirucotide (formerly referred to as MBP8298), if it reaches the market. In December 2007, BioMS sublicensed its rights in this product to Eli Lilly and Company. The FDA has granted the product fast track designation. We expect final trial data will be available during the second half of 2009 from the first of two ongoing Phase III trials of dirucotide for the treatment of secondary progressive multiple sclerosis. We expect results from the second Phase III trial should be available during the last half of 2010.

AutoImmune is a biopharmaceutical company involved in the development of treatments for autoimmune and cell-mediated inflammatory diseases and conditions.

Statements in this release that are not strictly historical are forward-looking statements including statements about clinical trials and studies and future sales, royalties and revenue. Statements in this release that are not strictly historical are forward-looking statements including statements about clinical trials and studies and future sales, royalties and revenue. You can identify these forward-looking statements because they involve our expectations, beliefs, projections, anticipations or other characterizations of future events or circumstances. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements as a result of any number of factors. These factors include, but are not limited to the uncertainties of clinical trial results, AutoImmune's dependence on third parties for licensing revenue, and the risks of technological change and competition. These factors are more fully discussed, as are other factors, in AutoImmune's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission in the section entitled "Risk Factors."

                            - Financial Chart Follows -



                                  AUTOIMMUNE INC.
                              STATEMENT OF OPERATIONS
                                    (Unaudited)

                                                           Three months ended
                                                                March 31,
                                                            2008        2009
                                                            ----        ----

      Revenue                                            $67,000    $104,000
                                                         -------    --------


      Costs and expenses:
        Cost of goods sold                                12,000      20,000
        Research and development                          42,000      71,000
        General and administrative                       205,000     188,000
                                                         -------     -------
          Total costs and expenses                       259,000     279,000
                                                         -------     -------

      Interest income                                     84,000       9,000
                                                          84,000       9,000
                                                          ------       -----

      Net loss                                          (108,000)   (166,000)
        Net income (loss) attributable to
         noncontrolling interest                           1,000      (4,000)
                                                           -----      ------

      Net loss attributable to AutoImmune Inc          ($107,000)  ($170,000)
                                                       =========   =========

      Net loss per share - basic                          ($0.01)     ($0.01)
                                                          ======      ======

      Net loss per share - diluted                        ($0.01)     ($0.01)
                                                          ======      ======

      Weighted average common shares
        outstanding - basic                           16,997,205  16,999,623
                                                      ==========  ==========

      Weighted average common shares
        outstanding - diluted                         16,997,205  16,999,623
                                                      ==========  ==========




                              CONDENSED BALANCE SHEET
                                    (Unaudited)

                                                    December 31,   March 31,
                                                        2008        2009
                                                        ----        ----


      Cash and marketable securities                  $8,475,000  $8,463,000
      Other current assets                               195,000     148,000

        Total assets                                  $8,670,000  $8,611,000
                                                      ==========  ==========

      Current liabilities                               $147,000    $228,000
      Total equity                                     8,523,000   8,383,000
                                                       ---------   ---------

      Total liabilities and equity                    $8,670,000  $8,611,000
                                                      ==========  ==========


'/>"/>
SOURCE Autoimmune Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes
2. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes - Correction
3. AutoImmune Inc. Reports 2007 Fourth Quarter and Year End Financial Results
4. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
5. AutoImmune Inc. Reports 2008 Third Quarter Financial Results
6. Advances in Detection Technology Drive the European Autoimmune Disease Diagnostics Market
7. AutoImmune Inc. Reports 2008 Fourth Quarter and Year End Financial Results
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... February 12, 2016 , ... The Pittcon 2016 Exposition, which ... will include 848 exhibitors (count as of February 9) of which 119 are ... used by the scientific community in industrial, academic, and government labs. The Exposition ...
(Date:2/12/2016)... FRANCISCO , February 12, 2016 ... Medicine Efforts by Enabling Scientific Understanding of Complex ... and Rare Diseases --> ... genomic diagnostics in South Asia and a leading provider ... would contribute $10 million to the GenomeAsia 100K ...
(Date:2/11/2016)... 2016  Vermillion, Inc. (NASDAQ: VRML ), a ... the formation of the Steering Committee for its Pelvic ... --> Pelvic masses can present physicians and healthcare ... pregnancy is ruled out, pelvic masses may include cancers ... benign ovarian tumors and gastrointestinal and urinary tract masses. ...
(Date:2/11/2016)... Feb. 11, 2016  Spectra BioPharma Selling Solutions (Spectra) ... provides biopharma companies the experience, expertise, operational delivery ... outsourced sales teams. Created in concert with industry ... the strategic and tactical needs of its clients ... through both personal and non-personal promotion. ...
Breaking Biology Technology:
(Date:1/22/2016)... DUBLIN , January 22, 2016 ... has announced the addition of the  ... to their offering. --> ... of the  "Global Behavioral Biometric Market ... --> Research and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ...
(Date:1/20/2016)... Jan. 20, 2016 A market that just ... benefit from the explosion in genomics knowledge. Learn all ... Research. A range of dynamic trends are pushing market ... personalized medicine - pharmacogenomics - pathogen evolution - next ... markets - greater understanding of the role of genetic ...
(Date:1/18/2016)... , Jan. 18, 2016  Extenua Inc., ... that simplifies the use and access of ubiquitous ... go-to-market partnership with American Cyber.  ... extensive experience leading transformational C4ISR and Cyber initiatives ... integrating the latest proven technology solutions," said ...
Breaking Biology News(10 mins):